The Thrombolysis in Myocardial Infarction (TIMI) trials: the first decade.

[1]  E. Braunwald,et al.  Predictors of non-Q-wave acute myocardial infarction in patients with acute ischemic syndromes: an analysis from the Thrombolysis in Myocardial Ischemia (TIMI) III trials. , 1995, The American journal of cardiology.

[2]  L. Shaw,et al.  Early and 1-year clinical outcome of patients' evolving non-Q-wave versus Q-wave myocardial infarction after thrombolysis. Results from The TIMI II Study. , 1995, Circulation.

[3]  J. Gore,et al.  Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction , 1995, Neurology.

[4]  C. Cannon,et al.  Angiographic predictors of reocclusion after thrombolysis: results from the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. , 1995, Journal of the American College of Cardiology.

[5]  C. Cannon,et al.  988-3 Is there a Circadian Variation in Anticoagulation Response to Hirudin Following Acute Myocardial Infarction? , 1995 .

[6]  E. Braunwald,et al.  731-1 Contemporary PTCA for Acute Coronary Ischemia: Results in Women Match Those of Men , 1995 .

[7]  E. Antman,et al.  755-2 Current Management of ST Elevation Myocardial Infarction and Outcome of Thrombolytic Ineligible Patients: Results of the Multicenter TIMI 9 Registry , 1995 .

[8]  E. Antman,et al.  1006-42 What Beyond Aspirin and Anticoagulation Improves Outcome in Unstable Angina? Effect of Medical Therapy , 1995 .

[9]  J. Kalbfleisch,et al.  715-5 Reteplase vs Alteplase Patency Investigation During Myocardial Infarction Trial (RAPID 2) , 1995 .

[10]  E. Braunwald,et al.  1000–39 Advanced Age Does not Diminish the Results of PTCA for Acute Ischemic Syndromes , 1995 .

[11]  C. Cannon,et al.  988-1 Toward Establishing Anticoagulation Guidelines for Intravenous Heparin Administration Among Patients with Myocardial Infarction Given Tissue Plasminogen Activator , 1995 .

[12]  E. Braunwald,et al.  How do smokers differ from nonsmokers in their response to thrombolysis? (the TIMI-4 trial) , 1995, The American journal of cardiology.

[13]  B. Gersh,et al.  Coronary artery bypass graft surgery after thrombolytic therapy in the Thrombolysis in Myocardial Infarction Trial, Phase II (TIMI II). , 1995, Journal of the American College of Cardiology.

[14]  C. Cannon,et al.  Previous angina alters in-hospital outcome in TIMI 4. A clinical correlate to preconditioning? , 1995, Circulation.

[15]  L. V. Lee,et al.  Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial. , 1995, The American journal of cardiology.

[16]  C. Cannon,et al.  Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. , 1994, Journal of the American College of Cardiology.

[17]  L. Wilkins.  Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. , 1994, Circulation.

[18]  U. Tebbe,et al.  Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK) , 1994, Circulation.

[19]  E. Antman.  Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. , 1994, Circulation.

[20]  E. Braunwald,et al.  Clinical and arteriographic characterization of patients with unstable angina without critical coronary arterial narrowing (from the TIMI-IIIA Trial). , 1994, The American journal of cardiology.

[21]  C. Shively,et al.  Determinants of Coronary Artery Reactivit in Premenopausal Female Cynomolgus Monkeys With Diet‐Induced Atherosclerosis , 1994, Circulation.

[22]  E. Braunwald,et al.  Comparison of patients with <60%to≥60% diameter narrowing of the myocardial infarct-related artery after thrombolysis , 1994 .

[23]  C. Cannon,et al.  Use of a standardized heparin nomogram to achieve therapeutic anticoagulation after thrombolytic therapy in myocardial infarction. TIMI 4 investigators. Thrombolysis in Myocardial Infarction. , 1994, Archives of internal medicine.

[24]  C Lenfant,et al.  NHLBI funding policies. Enhancing stability, predictability, and cost control. , 1994, Circulation.

[25]  B. Chaitman,et al.  Impact of Age on Clinical Outcome and Postlytic Management Strategies in Patients Treated With Intravenous Thrombolytic Therapy: Results From the TIMI II Study , 1994, Circulation.

[26]  D. Botstein,et al.  A faster-acting and more potent form of tissue plasminogen activator. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[27]  E. Braunwald,et al.  Comparison of Clinical Outcomes for Women and Men after Acute Myocardial Infarction , 1994, Annals of Internal Medicine.

[28]  W. Rogers,et al.  Effect on outcome of the presence or absence of chest pain at initiation of recombinant tissue plasminogen activator therapy in acute myocardial infarction. The Thrombolysis in Myocardial Infarction Investigators. , 1994, The American journal of cardiology.

[29]  L. Wilkins.  Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. , 1994, Circulation.

[30]  C. Cannon,et al.  A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. , 1994, Journal of the American College of Cardiology.

[31]  E. Braunwald,et al.  GUSTO, TIMI and the case for rapid reperfusion. , 1994, Acta cardiologica.

[32]  R. Califf,et al.  Individual risk assessment for intracranial haemorrhage during thrombolytic therapy , 1993, The Lancet.

[33]  E. Braunwald,et al.  Two- and three-year results of the thrombolysis in myocardial infraction (TIMI) phaes II clinical trial , 1993 .

[34]  T. Ryan,et al.  Incidence and significance of ventricular tachycardia and fibrillation in the absence of hypotension or heart failure in acute myocardial infarction treated with recombinant tissue-type plasminogen activator: Results from the thrombolysis in myocardial infarction (TIMI) phaes II trial , 1993 .

[35]  E. Braunwald.  The open-artery theory is alive and well--again. , 1993, The New England journal of medicine.

[36]  Gusto Angiographic Investigators.  The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. , 1993, The New England journal of medicine.

[37]  Craig D. Miller,et al.  Management of Patients With Intramural Hematoma of the Thoracic Aorta , 1993, Circulation.

[38]  E. Braunwald,et al.  Potential benefits of late reperfusion of infarcted myocardium. The open artery hypothesis. , 1993, Circulation.

[39]  W. Rogers,et al.  Race and Prognosis After Myocardial Infarction Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial , 1993, Circulation.

[40]  F. Sheehan,et al.  Effect of thrombolysis on acute mitral regurgitation during evolving myocardial infarction. Experience from the Thrombolysis in Myocardial Infarction (TIMI) Trial. , 1993, Journal of the American College of Cardiology.

[41]  B. Gersh,et al.  Thrombolysis and Myocardial Salvage Results of Clinical Trials and the Animal Paradigm‐ Paradoxic or Predictable? , 1993, Circulation.

[42]  A. Jacobs,et al.  Frequency and significance of right ventricular dysfunction during inferior wall left ventricular myocardial infarction treated with thrombolytic therapy (results from the Thrombolysis in Myocardial Infarction [TIMI] II trial) , 1993 .

[43]  E. Braunwald,et al.  Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. , 1993, The American journal of cardiology.

[44]  R. R. Wolfe,et al.  Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septal defects. , 1993, Circulation.

[45]  H. Sabbah,et al.  Hemodynamic correlates of the third heart sound during the evolution of chronic heart failure. , 1993, Journal of the American College of Cardiology.

[46]  L. Shaw,et al.  Impact of treatment strategy on predischarge exercise test in the Thrombolysis in Myocardial Infarction (TIMI) II Trial. , 1993, The American journal of cardiology.

[47]  L. Wilkins.  Early Effects of Tissue‐Type Plasminogen Activator Added to Conventional Therapy on the Culprit Coronary Lesion in Patients Presenting With Ischemic Cardiac Pain at Rest Results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trialx , 1993, Circulation.

[48]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.

[49]  A. Buchwald,et al.  Platelet and fibrin deposition on coronary stents in minipigs: effect of hirudin versus heparin. , 1993, Journal of the American College of Cardiology.

[50]  A. Jacobs,et al.  Invasive versus conservative strategy after thrombolytic therapy for acute myocardial infarction in patients with antecedent angina. A report from Thrombolysis in Myocardial Infarction Phase II (TIMI II). , 1992, Journal of the American College of Cardiology.

[51]  E. Braunwald,et al.  Modifiers of timing and possible triggers of acute myocardial infarction in the Thrombolysis in Myocardial Infarction Phase II (TIMI II) Study Group. , 1992, Journal of the American College of Cardiology.

[52]  M. Simoons,et al.  Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA). , 1992, Journal of the American College of Cardiology.

[53]  A. Jacobs,et al.  Incidence and prognostic implications of heart block complicating inferior myocardial infarction treated with thrombolytic therapy: results from TIMI II. , 1992, Journal of the American College of Cardiology.

[54]  E. Braunwald,et al.  An approach to evaluating thrombolytic therapy in acute myocardial infarction. The 'unsatisfactory outcome' end point. , 1992, Circulation.

[55]  J. Hsia,et al.  Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. HART Investigators. , 1992, Journal of the American College of Cardiology.

[56]  H. Dodge,et al.  Mitral Regurgitation in Early Myocardial Infarction , 1992, Annals of Internal Medicine.

[57]  G. Schuler,et al.  Regular Physical Exercise and Low‐Fat Diet: Effects on Progression of Coronary Artery Disease , 1992, Circulation.

[58]  B. Chaitman,et al.  Mechanisms of early death despite thrombolytic therapy: experience from the Thrombolysis in Myocardial Infarction Phase II (TIMI II) study. , 1992, Journal of the American College of Cardiology.

[59]  E. Braunwald,et al.  The rt-PA versus streptokinase. Controversy--II. , 1992, Journal of the American College of Cardiology.

[60]  C. Lenfant.  The rt-PA versus streptokinase. Controversy--I. , 1992, Journal of the American College of Cardiology.

[61]  J. Loscalzo,et al.  Effect of thrombin inhibition on the dynamics of thrombolysis and on platelet function during thrombolytic therapy. , 1992, Circulation research.

[62]  E. Braunwald,et al.  Predictors of Early Morbidity and Mortality After Thrombolytic Therapy of Acute Myocardial Infarction: Analyses of Patient Subgroups in the Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase II , 1992, Circulation.

[63]  M. Pfisterer,et al.  Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. , 1992, British heart journal.

[64]  E. Braunwald,et al.  One‐Year Results of the Thrombolysis in Myocardial Infarction Investigation (TIMI) Phase II Trial , 1992, Circulation.

[65]  E. Braunwald,et al.  Coronary Angioplasty Performed Within the Thrombolysis in Myocardial Infarction II Study , 1992, Circulation.

[66]  G. Knatterud,et al.  Assessment of global and regional left ventricular performance at rest and during exercise after thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) II Study. , 1992, The American journal of cardiology.

[67]  K. Mann,et al.  Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. , 1991, Annals of internal medicine.

[68]  A. DeMaria,et al.  A Prospective, Randomized Trial Comparing Combination Half‐Dose Tissue‐Type Plasminogen Activator and Streptokinase With Full-Dose Tissue‐Type Plasminogen Activator , 1991, Circulation.

[69]  Burton E. Sobel,et al.  Prevention of Arterial Reocclusion After Thrombolysis With Recombinant Lipoprotein‐Associated Coagulation Inhibitor , 1991, Circulation.

[70]  M. Perryman,et al.  Noninvasive detection of reperfusion in acute myocardial infarction based on plasma activity of creatine kinase MB subforms. , 1991, Journal of the American College of Cardiology.

[71]  B. G. Brown,et al.  Influence of coronary collateral vessels on myocardial infarct size in humans. Results of phase I thrombolysis in myocardial infarction (TIMI) trial. The TIMI Investigators. , 1991, Circulation.

[72]  F. Sheehan,et al.  Does arterial patency 90 minutes following thrombolytic therapy predict 42 day survival , 1991 .

[73]  E. Braunwald,et al.  Does left ventricular ejection fraction following thrombolytic therapy have the same prognostic impact described in the prethrombolytic era? Results of the TIMI II trail , 1991 .

[74]  W. Rogers,et al.  Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. , 1991, Circulation.

[75]  J. Gore,et al.  Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial. , 1991, Circulation.

[76]  E. Braunwald,et al.  Thrombolysis in Myocardial Infarction (TIMI) phase II trial: outcome comparison of a "conservative strategy" in community versus tertiary hospitals. The TIMI Research Group. , 1990, Journal of the American College of Cardiology.

[77]  J. Hsia,et al.  A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators. , 1990, The New England journal of medicine.

[78]  K. Mann,et al.  Fibrin fragment D-dimer and fibrinogen B beta peptides in plasma as markers of clot lysis during thrombolytic therapy in acute myocardial infarction. , 1990, Blood.

[79]  W J Penny,et al.  Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis. , 1990, Circulation.

[80]  E. Braunwald,et al.  Risk stratification before thrombolytic therapy in patients with acute myocardial infarction. The Thrombolysis in Myocardial Infarction (TIMI) Phase II Co-Investigators. , 1990, Journal of the American College of Cardiology.

[81]  R. Huber,et al.  The structure of a complex of recombinant hirudin and human alpha-thrombin. , 1990, Science.

[82]  B. Zaret,et al.  Silent left ventricular dysfunction during routine activity after thrombolytic therapy for acute myocardial infarction. , 1990, Journal of the American College of Cardiology.

[83]  J. Gore,et al.  Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II-A trial. , 1990, Circulation.

[84]  E. Braunwald,et al.  Cardiac morphologic findings in patients with acute myocardial infarction treated with recombinant tissue plasminogen activator. , 1990, The American journal of cardiology.

[85]  E. Braunwald,et al.  The Thrombolysis in Myocardial Infarction (TIMI) Trial phase II: additional information and perspectives. , 1990, Journal of the American College of Cardiology.

[86]  E. Braunwald,et al.  Tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty: one-year TIMI phase II pilot results. TIMI Investigators. , 1990, American heart journal.

[87]  L. Johnson,et al.  Dual isotope thallium and indium antimyosin SPECT imaging to identify acute infarct patients at further ischemic risk. , 1990, Circulation.

[88]  E. Ruiz,et al.  An analysis of time delays preceding thrombolysis for acute myocardial infarction. , 1989, JAMA.

[89]  U. Tebbe,et al.  Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. , 1989, Journal of the American College of Cardiology.

[90]  R. Califf,et al.  From myocardial salvage to patient salvage in acute myocardial infarction: the role of reperfusion therapy. , 1989, Journal of the American College of Cardiology.

[91]  R. Gibbons,et al.  Feasibility of tomographic 99mTc-hexakis-2-methoxy-2-methylpropyl-isonitrile imaging for the assessment of myocardial area at risk and the effect of treatment in acute myocardial infarction. , 1989, Circulation.

[92]  R. Gibbons,et al.  Serial quantitative planar technetium-99m isonitrile imaging in acute myocardial infarction: efficacy for noninvasive assessment of thrombolytic therapy. , 1989, Journal of the American College of Cardiology.

[93]  M. Talbot.  Biology of Recombinant Hirudin (CGP 39393): A New Prospect in the Treatment of Thrombosis , 1989, Seminars in thrombosis and hemostasis.

[94]  J. Bigger,et al.  A physiologically based model of creatine kinase-MB release in reperfusion of acute myocardial infarction. , 1989, The American journal of cardiology.

[95]  E. Braunwald,et al.  Quantitative radionuclide assessment of regional ventricular function after thrombolytic therapy for acute myocardial infarction: results of phase I Thrombolysis in Myocardial Infarction (TIMI) trial. , 1989, Journal of the American College of Cardiology.

[96]  E. Braunwald,et al.  Variables predictive of good functional outcome following thrombolytic therapy in the Thrombolysis in Myocardial Infarction phase II (TIMI II) pilot study. , 1989, The American journal of cardiology.

[97]  W J Penny,et al.  Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor. , 1989, Circulation.

[98]  J. Gore,et al.  Feasibility and safety of emergency interhospital transport of patients during early hours of acute myocardial infarction. , 1989, Archives of internal medicine.

[99]  E. Braunwald,et al.  Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded? , 1989, Circulation.

[100]  J. Mattera,et al.  Demonstration of reperfusion after thrombolysis with technetium-99m isonitrile myocardial imaging. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[101]  A. Jaffe,et al.  Prompt detection of myocardial injury by assay of creatine kinase isoforms in initial plasma samples , 1988, Clinical cardiology.

[102]  A. Jaffe,et al.  Characterization in vivo of the fibrin specificity of activators of the fibrinolytic system. , 1988, Circulation.

[103]  E. Braunwald,et al.  Six- and twelve-month follow-up of the phase I Thrombolysis in Myocardial Infarction (TIMI) trial. , 1988, The American journal of cardiology.

[104]  J. Alpert,et al.  Impact of thrombolytic therapy on left ventricular mural thrombi in acute myocardial infarction. , 1988, The American journal of cardiology.

[105]  A. Jaffe,et al.  Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase , 1988 .

[106]  G. Knatterud,et al.  Patient recruitment experience in the Thrombolysis in Myocardial Infarction Trial. , 1987, Controlled clinical trials.

[107]  B. Chaitman,et al.  The Thrombolysis in Myocardial Infarction (TIMI) phase II pilot study: tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty. , 1987, Journal of the American College of Cardiology.

[108]  S. Forman,et al.  Coronary angioplasty after recombinant tissue-type plasminogen activator in acute myocardial infarction: a report from the Thrombolysis in Myocardial Infarction (TIMI) Trial. , 1987, Journal of the American College of Cardiology.

[109]  E. Braunwald,et al.  Update from the Thrombolysis in Myocardial Infarction Trial. , 1987, Journal of the American College of Cardiology.

[110]  S. Forman,et al.  Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator. , 1987, Journal of the American College of Cardiology.

[111]  R. Bolli,et al.  Activation of the complement system by recombinant tissue plasminogen activator. , 1987, Journal of the American College of Cardiology.

[112]  T. Robertson.  Myocardial infarction: systemic thrombolysis in the U.S.A. , 1987, European heart journal.

[113]  R Roberts,et al.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.

[114]  J. Gore,et al.  Peak creatine kinase as a measure of effectiveness of thrombolytic therapy in acute myocardial infarction. , 1987, The American journal of cardiology.

[115]  K. Friedman,et al.  Quantitation of fragment X formation during thrombolytic therapy with streptokinase and tissue plasminogen activator. , 1987, The Journal of clinical investigation.

[116]  D. Gehring,et al.  Comparison of monoplane and biplane assessment of regional left ventricular wall motion after thrombolytic therapy for acute myocardial infarction. , 1987, The American journal of cardiology.

[117]  F H Sheehan,et al.  The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial. , 1987, Circulation.

[118]  E. Braunwald,et al.  Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial. , 1986, Circulation.

[119]  E. Braunwald,et al.  Circadian variation in the frequency of onset of acute myocardial infarction. , 1985, The New England journal of medicine.

[120]  E. Braunwald,et al.  High dose intravenous streptokinase for acute myocardial infarction: preliminary results of a multicenter trial. , 1985, Journal of the American College of Cardiology.

[121]  A. Reinberg,et al.  Circadian changes in anticoagulant effect of heparin infused at a constant rate. , 1985, British medical journal.

[122]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.

[123]  F. Markwardt,et al.  Pharmacokinetics and Anticoagulant Effect of Hirudin in Man , 1984, Thrombosis and Haemostasis.